Merck Ready to Submit Belsomra to FDA for Alzheimer's Insomnia

Merck & Company’s Belsomra (suvorexant) was approved to treat insomnia in August 2014. The company announced today that it had positive results in a Phase III clinical trial evaluating the drug for insomnia in patients with mild-to-moderate Alzheimer’s disease dementia. Merck presented the data at the American Academy of Neurology (AAN) Annual Meeting this week.